Callan Family Office LLC Takes Position in GSK plc (NYSE:GSK)

Callan Family Office LLC acquired a new stake in GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 57,712 shares of the pharmaceutical company’s stock, valued at approximately $1,952,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sunbelt Securities Inc. raised its holdings in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co raised its holdings in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new stake in shares of GSK in the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK in the fourth quarter valued at approximately $32,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GSK has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Trading Up 2.0 %

GSK stock opened at $40.08 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company has a fifty day moving average price of $35.47 and a two-hundred day moving average price of $37.20. GSK plc has a one year low of $31.72 and a one year high of $45.92. The stock has a market cap of $83.07 billion, a price-to-earnings ratio of 25.21, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.